Generics Portfolio
Various (ANDAs)
Pre-approval & CommercialActive
Key Facts
About ANI Pharmaceuticals
ANI Pharmaceuticals is a publicly traded, integrated specialty pharmaceutical company with a market valuation of approximately $1.67 billion. Founded in 2001 and headquartered in Baudette, Minnesota, USA, the company has evolved from a generics-focused entity into a diversified biopharmaceutical firm with a strategic pivot towards building a leading rare disease franchise. It sustains growth through three core segments: a Rare Disease business marketing novel products, a Generics business leveraging U.S.-based manufacturing, and an Established Brands portfolio. Recent financial performance has been strong, with record results reported for 2025 and reaffirmed guidance for 2026.
View full company profileTherapeutic Areas
Other Various (ANDAs) Drugs
| Drug | Company | Phase |
|---|---|---|
| Generic Product Development | Mission Pharmacal | Development/ANDA Submission |